modelJ05AP10
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Elbasvir | |
| ATC code: | J05AP10 | route: | oral |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 680 | L |
| clearance: | 23 | L/hr |
| other parameters in model implementation | ||
Elbasvir is an oral, direct-acting antiviral drug that acts as an inhibitor of the hepatitis C virus (HCV) NS5A protein, which is essential for viral replication. It is approved for use in combination with grazoprevir in the treatment of chronic HCV infection in adults. Elbasvir is currently used in clinical practice.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult subjects after a single oral dose.
References
Marshall, WL, et al., & Yeh, WW (2018). Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment. European journal of drug metabolism and pharmacokinetics 43(3) 321–329. DOI:10.1007/s13318-017-0451-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29247332
Landaverde, C, et al., & Goldstein, JL (2016). Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection. Expert review of gastroenterology & hepatology 10(4) 419–429. DOI:10.1586/17474124.2016.1147346 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26818134
Roth, D, et al., & Greaves, W (2015). Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet (London, England) 386(10003) 1537–1545. DOI:10.1016/S0140-6736(15)00349-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26456905
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)